Summary

Cerebrolysin is a complex mixture of low-molecular-weight peptides and free amino acids derived from enzymatic hydrolysis of porcine brain proteins. It mimics the effects of endogenous neurotrophic factors (BDNF, NGF, GDNF) and has been investigated in over 200 clinical studies for stroke recovery, traumatic brain injury, and dementia. It is licensed in several countries (Austria, Russia, China) but is not approved by the MHRA, EMA, or FDA. For research purposes, it is supplied as a ready-to-use injectable solution rather than a lyophilised powder.

Mechanism

Cerebrolysin's mechanism is multi-modal, reflecting its composition of neurotrophic peptides and free amino acids. It is thought to mimic the effects of endogenous neurotrophic factors including BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and GDNF (glial cell line-derived neurotrophic factor). Key mechanisms include: (1) neuroprotection — reducing excitotoxicity, calcium overload, and oxidative stress in neurons; (2) neurotrophic support — promoting neuronal survival, neurite outgrowth, and synaptic plasticity; (3) anti-apoptotic effects — modulating caspase pathways and protecting against programmed cell death; and (4) metabolic support — providing amino acids that serve as precursors for neurotransmitter synthesis. The multi-component nature of Cerebrolysin means that its effects cannot be attributed to a single peptide but rather to the combined action of its constituents.

Protocols

In clinical trials, Cerebrolysin has been administered intravenously at 10–50 mL/day (1 mL = 215.2 mg concentrate), diluted in saline and infused over 15–60 minutes. Treatment cycles typically run 10–21 days. In research/community discussion, 5–10 mL/day for 10–20 days is commonly mentioned. These figures are from published literature only; Cerebrolysin is not licensed in the UK.

Cerebrolysin is not licensed by the MHRA in the UK and does not hold EMA marketing authorisation. It is approved in several countries including Austria, Russia, and China. Importing it without a valid prescription is unlawful. As a research compound, it may be used for legitimate laboratory research but not for human consumption in the UK.

Vendor notes

Cerebrolysin is not commonly stocked by UK research peptide suppliers as it is supplied as a finished pharmaceutical injectable rather than a lyophilised research chemical. Researchers may need to source it internationally. Exercise caution regarding provenance, cold-chain storage, and authenticity.

References

  1. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. doi:10.1161/STROKEAHA.111.628567
  2. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-159. doi:10.1161/STROKEAHA.115.011460
  3. Liu J, Wang LN. Cerebrolysin for traumatic brain injury. Cochrane Database Syst Rev. 2012;(5):CD008415. doi:10.1002/14651858.CD008415.pub2
  4. Chen H, Yu S, Chen C, et al. Cerebrolysin in the treatment of acute ischemic stroke: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020;99(31):e21427. doi:10.1097/MD.0000000000021427
  5. Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006;13(1):43-54. doi:10.1111/j.1468-1331.2006.01222.x
  6. Zhang L, Chopp M, Jia L, et al. Cerebrolysin enhances neurogenesis in the ischemic boundary zone after experimental stroke. J Neurosci Res. 2010;88(15):3279-3290. doi:10.1002/jnr.22459